|
84 Companies |
|
139 Products |
|
139 Products |
|
62 Mechanisms of Action |
|
7 Trials |
|
632 News |
|
| «12345678910111213...1314» |
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma, Rituxan (rituximab) / Roche
New P1 trial, Combination therapy: CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jun 22, 2014
P1, N=14, Not yet recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
- methoxyamine (TRC102) / Tracon Pharma
Enrollment closed: Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies (clinicaltrials.gov) - Jun 22, 2014
P1, N=30, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
Recruiting --> Active, not recruiting
- fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg.
Trial primary completion date: Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer (clinicaltrials.gov) - Jun 19, 2014
P2, N=100, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2014 --> Dec 2015
- | Kymriah (tisagenlecleucel-T) / Novartis
New P2 trial: Study of Efficacy and Safety of CTL019 in Adult ALL Patients (clinicaltrials.gov) - Jun 19, 2014
P2, N=67, Recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
- fludarabine IV / Generic mfg., busulfan / Generic mfg.
Trial primary completion date: Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease (clinicaltrials.gov) - Jun 18, 2014
P2, N=70, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Trial primary completion date: Dec 2014 --> Dec 2015 Trial primary completion date: Dec 2013 --> Dec 2015
- peripheral blood stem cell transplantation / National Cancer Institute
Trial termination: Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer (clinicaltrials.gov) - Jun 4, 2014
P2, N=48, Terminated, Sponsor: Columbia University
Trial primary completion date: Dec 2013 --> Dec 2015 Recruiting --> Terminated; Poor enrollment
- peripheral blood stem cell transplantation / National Cancer Institute
Trial initiation date: Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer (clinicaltrials.gov) - Jun 4, 2014
P2, N=48, Terminated, Sponsor: Columbia University
Recruiting --> Terminated; Poor enrollment Initiation date: Jan 1997 --> Jul 1996
- peripheral blood stem cell transplantation / National Cancer Institute
Enrollment change: Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer (clinicaltrials.gov) - Jun 4, 2014
P2, N=48, Terminated, Sponsor: Columbia University
Initiation date: Jan 1997 --> Jul 1996 N=62 --> 48
- dasatinib / Generic mfg.
Enrollment closed, Surgery, Metastases: Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery (clinicaltrials.gov) - Jun 2, 2014
P1, N=42, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=62 --> 48 Recruiting --> Active, not recruiting
- Imbruvica (ibrutinib) / AbbVie, J&J
Trial primary completion date: Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jun 1, 2014
P2, N=20, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2014 --> Jun 2015
- | Genasense (oblimersen) / Genta, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion: Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - May 26, 2014
P2, N=48, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2014 --> Jun 2015 Active, not recruiting --> Completed
- Zolinza (vorinostat) / Merck (MSD), alisertib (MLN8237) / Puma
Trial primary completion date, Combination therapy, Epigenetic controller: Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma (clinicaltrials.gov) - May 26, 2014
P1, N=60, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial primary completion date: Jun 2014 --> Apr 2015
- | Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap, patupilone (EPO 906) / Novartis
Trial completion: Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (clinicaltrials.gov) - May 25, 2014
P2, N=51, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2014 --> Apr 2015 Active, not recruiting --> Completed
- Yervoy (ipilimumab) / BMS
Trial termination, IO biomarker: MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma (clinicaltrials.gov) - May 21, 2014
P1/2, N=18, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Completed --> Terminated
- Yervoy (ipilimumab) / BMS
Enrollment change, IO biomarker: MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma (clinicaltrials.gov) - May 21, 2014
P1/2, N=36, Completed, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated N=18 --> 36
- Zolinza (vorinostat) / Merck (MSD)
Enrollment closed: Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies (clinicaltrials.gov) - May 18, 2014
P2, N=12, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=18 --> 36 Recruiting --> Active, not recruiting
- | Rituxan (rituximab) / Roche
Trial completion, Metastases: Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma (clinicaltrials.gov) - May 12, 2014
P2, N=106, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Genasense (oblimersen) / Genta, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment change: Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - May 12, 2014
P2, N=120, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=48 --> 120
- | mycophenolate mofetil / Generic mfg.
Trial completion: Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers (clinicaltrials.gov) - May 4, 2014
P2, N=20, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=48 --> 120 Active, not recruiting --> Completed
- | Trial completion: Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation (clinicaltrials.gov) - May 4, 2014
P=N/A, N=0, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Imbruvica (ibrutinib) / AbbVie, J&J
New P2 trial: Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 30, 2014
P2, N=20, Recruiting, Sponsor: National Cancer Institute (NCI)
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
Trial completion: Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease (clinicaltrials.gov) - Apr 30, 2014
P3, N=50, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- obatoclax (GX 15-070) / Teva
Enrollment change, Combination therapy: Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia (clinicaltrials.gov) - Apr 29, 2014
P1, N=22, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=52 --> 22
- MK-2206 / Merck (MSD)
Enrollment change: MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia (clinicaltrials.gov) - Apr 27, 2014
P1, N=45, Completed, Sponsor: National Cancer Institute (NCI)
N=52 --> 22 N=96 --> 45
- Rituxan (rituximab) / Roche
Enrollment change, Metastases: Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Apr 27, 2014
P2, N=70, Completed, Sponsor: National Cancer Institute (NCI)
N=96 --> 45 N=106 --> 70
- New P2 trial: Treg Cells for AGVHD in Non-myeloablative UCB Transplant (clinicaltrials.gov) - Apr 17, 2014
P2, N=18, Not yet recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
- | cyclosporine ophthalmic emulsion / Generic mfg.
Enrollment change: Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder (clinicaltrials.gov) - Apr 16, 2014
P3, N=165, Active, not recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
N=106 --> 70 N=256 --> 165
- | cyclosporine ophthalmic emulsion / Generic mfg.
Enrollment closed: Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder (clinicaltrials.gov) - Apr 16, 2014
P3, N=165, Active, not recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
N=256 --> 165 Recruiting --> Active, not recruiting
- sirolimus / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Clinical: A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy (clinicaltrials.gov) - Apr 15, 2014
P=N/A, N=7, Completed, Sponsor: Thomas Jefferson University
Recruiting --> Active, not recruiting Trial completion date: Jan 2014 --> Apr 2013
- | Trial completion: A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy (clinicaltrials.gov) - Apr 15, 2014
P=N/A, N=7, Completed, Sponsor: Thomas Jefferson University
Trial completion date: Jan 2014 --> Apr 2013 Active, not recruiting --> Completed
- | Enrollment change: Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer (clinicaltrials.gov) - Apr 15, 2014
P3, N=72, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed N=206 --> 72
- Imbruvica (ibrutinib) / AbbVie, J&J
New P1 trial: Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection (clinicaltrials.gov) - Apr 7, 2014
P1, N=78, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- Enrollment change: Combination Chemotherapy With or Without Total-Body Irradiation Followed By Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma (clinicaltrials.gov) - Mar 26, 2014
P2, N=60, Completed, Sponsor: City of Hope Medical Center
N=206 --> 72 N=85 --> 60
- Cytovene (ganciclovir) / Roche
Enrollment change: Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant (clinicaltrials.gov) - Mar 26, 2014
P2, N=61, Completed, Sponsor: City of Hope Medical Center
N=85 --> 60 N=24 --> 61
- Beleodaq (belinostat) / Aurobindo, Assertio
Enrollment change: PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Mar 23, 2014
P2, N=22, Completed, Sponsor: National Cancer Institute (NCI)
N=24 --> 61 N=40 --> 22
- RG4733 / Roche
Enrollment change, Combination therapy: RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors (clinicaltrials.gov) - Mar 19, 2014
P1, N=30, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=40 --> 22 N=40 --> 30
- fludarabine IV / Generic mfg., busulfan / Generic mfg.
Enrollment change: Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers (clinicaltrials.gov) - Mar 19, 2014
P2, N=1, Completed, Sponsor: University of California, Davis
N=40 --> 30 N=20 --> 1
- cyclophosphamide / Generic mfg., busulfan / Generic mfg.
Enrollment closed, Post-transplantation: Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer (clinicaltrials.gov) - Mar 19, 2014
P2, N=92, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=20 --> 1 Completed --> Active, not recruiting
- fludarabine IV / Generic mfg., busulfan / Generic mfg.
Trial completion: Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers (clinicaltrials.gov) - Mar 19, 2014
P2, N=1, Completed, Sponsor: University of California, Davis
Completed --> Active, not recruiting Active, not recruiting --> Completed
- cyclophosphamide / Generic mfg., thiotepa / Generic mfg.
Enrollment change: Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer (clinicaltrials.gov) - Mar 17, 2014
P2, N=25, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed N=50 --> 25
- busulfan / Generic mfg.
Enrollment open: Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant (clinicaltrials.gov) - Mar 17, 2014
P0, N=30, Recruiting, Sponsor: Case Comprehensive Cancer Center
N=50 --> 25 Not yet recruiting --> Recruiting
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion: Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma (clinicaltrials.gov) - Mar 12, 2014
P2, N=43, Completed, Sponsor: University of Washington
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Trial withdrawal: Early Detection of Graft-Versus-Host Disease in Patients Undergoing a Donor Bone Marrow Transplant (clinicaltrials.gov) - Mar 5, 2014
P=N/A, N=0, Withdrawn, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Active, not recruiting --> Withdrawn
- Enrollment change: Early Detection of Graft-Versus-Host Disease in Patients Undergoing a Donor Bone Marrow Transplant (clinicaltrials.gov) - Mar 5, 2014
P=N/A, N=0, Withdrawn, Sponsor: Mayo Clinic
Active, not recruiting --> Withdrawn N=46 --> 0
- Trial withdrawal: T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies (clinicaltrials.gov) - Mar 3, 2014
P1/2, N=0, Withdrawn, Sponsor: Masonic Cancer Center, University of Minnesota
N=46 --> 0 Not yet recruiting --> Withdrawn
- Enrollment change: T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies (clinicaltrials.gov) - Mar 3, 2014
P1/2, N=0, Withdrawn, Sponsor: Masonic Cancer Center, University of Minnesota
Not yet recruiting --> Withdrawn N=15 --> 0
- ||| Enrollment open, IO biomarker: Prognostic Potential Cell Surface Markers CD47 / CD27 / CD8 and Pim-kinase in Patients With Hematologic Malignancies or Solid Tumors (clinicaltrials.gov) - Mar 3, 2014
P=N/A, N=150, Recruiting, Sponsor: Cancer Centre of Monoclonal Therapy, LLC
N=15 --> 0 Active, not recruiting --> Recruiting
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion: Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases (clinicaltrials.gov) - Mar 3, 2014
P3, N=230, Completed, Sponsor: The Canadian Blood and Marrow Transplant Group
Active, not recruiting --> Recruiting Recruiting --> Completed
- ||||| vincristine / Generic mfg.
Enrollment change: AALL0433: Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Feb 27, 2014
P3, N=275, Active, not recruiting, Sponsor: Children's Oncology Group
Recruiting --> Completed N=418 --> 275
- ||||| vincristine / Generic mfg.
Enrollment closed: AALL0433: Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Feb 27, 2014
P3, N=275, Active, not recruiting, Sponsor: Children's Oncology Group
N=418 --> 275 Suspended --> Active, not recruiting